Sunscreen and Skin Cancer Risk: The 2018 Evidence Explained
Sunscreen is widely promoted across public health initiatives as an essential tool to shield skin from solar exposure. However, researchers continuously review observational studies to understand real-world outcomes across general populations. A major systematic review published in 2018 pooled decades of international research to evaluate whether reported sunscreen use correlated with lower rates of skin malignancies. Here is an objective look at the study design, numerical findings, historical shifts, and inherent limits of that research.
What Did the 2018 Meta-Analysis Investigate?
In 2018, the European journal of dermatology : EJD published a paper titled "Use of sunscreen and risk of melanoma and non-melanoma skin cancer: a systematic review and meta-analysis." The authors set out to assess the association between sunscreen use and the risk of developing skin malignancies. To gather data, the investigators searched PubMed, BIREME, and Google Scholar from their inception dates up through May 17, 2017.
The investigators gathered observational studies and controlled trials to determine whether regular or historical use of sunscreen demonstrated a clear preventive link. They synthesized the compiled data using a random-effects model to execute both conventional and cumulative meta-analyses, as outlined in the European journal of dermatology : EJD systematic review.
How Many Studies and Participants Were Included?
The meta-analysis evaluated a large pool of clinical and epidemiological publications. In total, the researchers identified and included 29 studies. The dataset captured information from 313,717 participants, including 10,670 confirmed cases of skin cancer.
The design of the underlying studies varied significantly across the literature:
- 25 case-control studies
- Two cohort studies
- One cross-sectional study
- One controlled trial
Because the overwhelming majority of the included publications were observational case-control studies, participants often had to self-report their prior sun habits and sunscreen application patterns after receiving a diagnosis.
What Were the Numerical Findings for Skin Cancer?
The primary analysis across all combined skin cancer categories did not establish a statistically significant association with sunscreen use, demonstrating an overall pooled odds ratio of 1.08 with high statistical heterogeneity (I2 = 89.4%).
When researchers separated the data into specific types of skin cancer, the results showed similar patterns:
- Melanoma: The analysis incorporated 25 studies with 9,813 cases. The pooled odds ratio was 1.10 (95% CI: 0.92-1.33).
- Non-melanoma skin cancer: The review examined five studies representing 857 cases, yielding a pooled odds ratio of 0.99 (95% CI: 0.62-1.57).
Because the confidence intervals spanned across neutral values, the authors concluded that this systematic review did not confirm the expected protective benefits of sunscreen against skin cancer in the general population.
Why Have Historical Findings Shifted Over Time?
A notable aspect of the paper was its cumulative meta-analysis, which mapped how reported outcomes changed across decades. Prior to the 1980s, the cumulative evidence showed a relatively strong positive association between melanoma and sunscreen use, recording a cumulative odds ratio of 2.35 (95% CI: 1.66-3.33). In those earlier records, individuals using sunscreen appeared more likely to be diagnosed with melanoma.
However, the strength of that association steadily decreased beginning in the early 1980s. By the early 1990s, the association had attenuated to the point where it was no longer statistically significant. Researchers often attribute these historical changes to improvements in sunscreen formulations, shifting public awareness regarding full-body coverage, and earlier detection programs.
What Are the Key Limitations of This Study?
While the paper provides valuable context, readers should recognize several critical limits before drawing sweeping conclusions:
- Predominance of observational data: With 25 case-control designs and only one controlled trial among the 29 studies, recall bias presents a major limitation. People with fair skin or prior sunburns may naturally use sunscreen more frequently, distorting raw risk comparisons.
- Substantial heterogeneity: The overall analysis recorded an I2 value of 89.4%, indicating wide variation in study methods, population genetics, geographic locations, and product formulations over several decades.
- No observed risk increase: Importantly, the researchers noted that current evidence suggests no increased risk of skin cancer related to sunscreen use, even though the expected protective reduction was not confirmed in population-level averages.
How Does This Relate to Broader Sun Safety?
Understanding clinical literature helps individuals make informed health choices rather than relying on unproven tanning shortcuts. Products marketed online such as melanotan I and melanotan II are completely unapproved and unregulated, carrying serious documented health risks. Medical professionals strongly discourage using unlicensed peptides to darken skin.
Instead, evidence-based sun defense relies on combining multiple protective strategies. Selecting appropriate broad-spectrum lotions—detailed further in our guide to sunscreen SPF and broad spectrum protection—remains standard medical advice alongside seeking shade and wearing protective clothing. For personalized skin checks or concerns regarding moles, always consult a qualified doctor or board-certified dermatologist.
Sources
Published October 28, 2026. Sources are linked in the text. See our Medical Disclaimer.